Cell-penetrating peptides (CPPs) are short peptides (fewer than 30 amino acids) that have
been predominantly used in basic and preclinical research during the last 30 years. Since …

Cancer is currently ineffectively treated using therapeutic drugs, and is also able to resist
drug action, resulting in increased side effects following drug treatment. A novel therapeutic …

In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics
especially peptides and proteins. In the intervening period, analysis of the preclinical and …

Protein and peptide drugs are predominantly administered by injection to achieve high
bioavailability, but this greatly compromises patient compliance. Oral and transdermal drug …

Biological cell membranes are a natural barrier for living cells. In the last few decades, the
cell membrane has been the main hurdle in the efficient delivery of bioactive and therapeutic …

Therapeutic efficacy against cancer relies heavily on the ability of the therapeutic agents to
reach their final targets. The optimal targets of most cancer therapeutic agents are usually …

Due to the poor physicochemical properties of drugs and multi-stage biological barriers in
vivo, drugs at action site cannot reach up to sufficient concentration to acquire expected …

In recent decades, peptides, which can possess high potency, excellent selectivity, and low
toxicity, have emerged as promising therapeutics for cancer applications. Combined with an …

Introduction Cell-penetrating peptide (CPP) technologies represent an important strategy to
address drug delivery to specific intracellular compartments by covalent conjugation to …

Cancer has become the primary reason for industrial countries death. Although first-line
treatments have achieved remarkable results in inhibiting tumors, they could have serious …